Danaher (DHR) Q3 2026 Earnings Call Transcript

Danaher reported Q3 2026 revenue of $6.6 billion, up 8.5% year over year, with core revenue growth of 5.5% excluding respiratory revenue, adjusted EPS of $2.11 (up 11.5%), and a 29.0% adjusted operating margin, 110 bps above the prior year. Results exceeded management’s expectations, and FY 2026 adjusted EPS guidance was raised to $8.57–$8.62 from $8.45–$8.60; Q4 core growth guidance is 4%–5% excluding respiratory revenue, which is expected to be a 150 bps headwind. Management set a 2027 starting point of 4%–5% core growth excluding respiratory, while noting academic demand remains below historical levels and flu-season variability could move respiratory revenue by a couple hundred million dollars around its $1.5 billion projection. The company also highlighted mid-teens bioprocessing order growth, Masimo’s high-single-digit revenue growth, the StatLab acquisition, and AI lab initiatives, including a workflow designed to accelerate reagent discovery up to eight times faster.

Analysis

DHR: improving demand is not yet an acceleration thesis. The key valuation question is whether better orders convert into sustained consumables growth and share gains—not whether one quarter clears internal expectations. Stronger bioprocessing orders are a useful lead signal, but equipment projects can be lumpy; monitor backlog conversion and consumables growth for evidence that demand is broadening. Management’s 2027 starting framework effectively caps near-term expectations: a multiple expansion needs execution above that bar, not just recovery in end markets.

The new CEO’s commercial and cross-selling agenda could lift wallet share without relying on acquisitions, but the “connected Danaher” model adds coordination and incentive complexity. Watch for segment-level share evidence and profitable growth; opportunity funnels alone are not revenue. Margin improvement also deserves a quality check: separate repeatable operating gains from temporary items, including tariff-related benefits.

Respiratory remains a material quarterly swing factor, especially for Diagnostics and North America. A weak season can obscure underlying growth, while a stronger season may flatter reported results without improving the structural run rate. China’s improvement and healthier biotech funding are supportive, but academic spending remains a potential drag. Competitors such as Thermo Fisher Scientific, Sartorius, and Repligen could face stronger competition if Danaher converts its broad workflow offering into share gains.

AI/autonomous labs are strategic optionality, not a near-term earnings driver. The NVIDIA collaboration may support adoption of connected workflows, but the call provides no economics to underwrite material NVDA revenue impact. The contrarian risk is that investors capitalize AI and CEO ambition before measurable commercial proof; the upside case is durable share capture beyond the current recovery. Near-term catalyst: Q4 conversion and January guidance. Structural test: share gains and profitable core growth over the next 6–18 months.

Key Decisions for Investors

• DHR: favor a measured long on market weakness rather than chasing the results. Reassess after Q4 and January guidance; upside depends on growth exceeding the current baseline and operating gains proving repeatable. Falsify if order strength fails to convert into consumables growth or guidance is cut.
• Track DHR’s bioprocessing backlog conversion, segment share indicators, and academic demand as 1–3 month alerts. Strong orders without follow-through in revenue would weaken the recovery thesis.
• Treat respiratory revenue as a reported-growth swing, not a core thesis driver. Normalize Diagnostics comparisons for seasonality; a flu-driven beat alone is not a reason to add exposure.
• No incremental NVDA position on this announcement: the partnership is strategically relevant but lacks disclosed commercial scale or timing. Revisit only with evidence of monetization or material customer deployment.